Neurocrine Biosciences Inc
(STU:NB3)
€
153.15
-1.9 (-1.23%)
Market Cap: 15.37 Bil
Enterprise Value: 14.57 Bil
PE Ratio: 26.83
PB Ratio: 5.14
GF Score: 93/100 Neurocrine Biosciences, Inc at William Blair Growth Stock Conference Transcript
Jun 02, 2026 / 03:40PM GMT
Release Date Price:
€132.7
(-3.98%)
Myles Minter
William Blair Capital Partners - Analyst
Thank you everyone for joining us here at the 46th William Blair Annual Growth Stock Conference. I haven't been here for all 46 years, but I have been here for close to 10. My name is Myles Minter. I'm a senior biotech analyst here at the firm. I cover the neurosciences and then genetic medicines, and it is my pleasure today to introduce Matt Abernethy, the CFO; and also to my right, Todd Tushla, Head of IR at Neurocrine Sciences, fresh from the West Coast.
So thanks very much for attending.
Matthew Abernethy
Neurocrine Biosciences, Inc - Chief Financial Officer
Myles, did disclose that he just came from Scotland. Is that right?
Myles Minter
William Blair Capital Partners - Analyst
I did. I did.
Matthew Abernethy
Neurocrine Biosciences, Inc - Chief Financial Officer
And my last name is Abernethy, and that's Scottish. You can get some cookies ever go to that town, but really glad to be here. I went to
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot